MA39915A - Composés de pladiénolide pyridine et leurs procédés d'utilisation - Google Patents

Composés de pladiénolide pyridine et leurs procédés d'utilisation

Info

Publication number
MA39915A
MA39915A MA039915A MA39915A MA39915A MA 39915 A MA39915 A MA 39915A MA 039915 A MA039915 A MA 039915A MA 39915 A MA39915 A MA 39915A MA 39915 A MA39915 A MA 39915A
Authority
MA
Morocco
Prior art keywords
processes
pyridine compounds
pladienolide pyridine
pladienolide
compounds
Prior art date
Application number
MA039915A
Other languages
English (en)
Other versions
MA39915B1 (fr
Inventor
Kenzo Arai
Silvia Buonamici
Betty Chan
Nicholas C Gearhart
Baudouin Gerard
Sonobe Regina Kanada
Gregg F Keaney
Kazunobu Kira
Yoshihiko Kotake
Kian Huat Lim
Xiang Liu
Masayuki Miyano
Norio Murai
Satoshi Nagao
Eunice Sun Park
Ermira Pazolli
Sudeep Prajapati
Peter G Smith
Michael P Thomas
Parcharee Tivitmahaisoon
John Wang
Lihua Yu
Guo Zhu Zheng
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39915(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA39915A publication Critical patent/MA39915A/fr
Publication of MA39915B1 publication Critical patent/MA39915B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA39915A 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation MA39915B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993423P 2014-05-15 2014-05-15
EP15727125.5A EP3143016B1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation
PCT/US2015/030464 WO2015175594A1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA39915A true MA39915A (fr) 2017-03-22
MA39915B1 MA39915B1 (fr) 2019-05-31

Family

ID=53284528

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39915A MA39915B1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation

Country Status (36)

Country Link
US (1) US9481669B2 (fr)
EP (2) EP3514154B1 (fr)
JP (1) JP6067943B1 (fr)
KR (2) KR102146726B1 (fr)
CN (1) CN107074827B (fr)
AR (1) AR100431A1 (fr)
AU (1) AU2015259237B2 (fr)
BR (1) BR112016026638B1 (fr)
CA (1) CA2947754C (fr)
CL (1) CL2016002835A1 (fr)
CY (1) CY1121550T1 (fr)
DK (1) DK3143016T3 (fr)
ES (1) ES2712401T3 (fr)
HR (1) HRP20190432T1 (fr)
HU (1) HUE041838T2 (fr)
IL (1) IL248529B (fr)
JO (1) JO3668B1 (fr)
LT (1) LT3143016T (fr)
MA (1) MA39915B1 (fr)
ME (1) ME03417B (fr)
MX (2) MX373324B (fr)
MY (1) MY195081A (fr)
PE (1) PE20170384A1 (fr)
PH (1) PH12016502249B1 (fr)
PL (1) PL3143016T3 (fr)
PT (1) PT3143016T (fr)
RS (1) RS58400B1 (fr)
RU (1) RU2707730C2 (fr)
SG (1) SG11201609693XA (fr)
SI (1) SI3143016T1 (fr)
SM (1) SMT201900158T1 (fr)
TR (1) TR201902328T4 (fr)
TW (1) TWI634115B (fr)
UA (1) UA119458C2 (fr)
WO (1) WO2015175594A1 (fr)
ZA (1) ZA201607354B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6876680B2 (ja) 2015-09-01 2021-05-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント
BR112018009995B1 (pt) 2015-11-18 2024-04-30 Eisai R&D Management Co., Ltd Forma cristalina, composição farmacêutica, e, uso da forma cristalina
CA3056389A1 (fr) 2017-03-15 2018-09-20 Eisai R&D Management Co., Ltd. Mutations de complexes d'epissage et leurs utilisations
MX2020004179A (es) * 2017-10-31 2020-08-03 Eisai R&D Man Co Ltd Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
SG11202009906TA (en) * 2018-04-09 2020-11-27 Eisai R&D Man Co Ltd Pladienolide compounds and their use
CA3096424A1 (fr) * 2018-04-12 2019-10-17 Eisai R&D Management Co., Ltd. Derives de pladienolide en tant qu'agents ciblant un complexe d'epissage pour le traitement du cancer
CN119405832A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
EP3801523B1 (fr) 2018-06-01 2024-09-11 Eisai R&D Management Co., Ltd. Modulateurs d'épissage
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
AU2021284401A1 (en) * 2020-06-05 2023-01-05 Eisai R&D Management Co., Ltd. Anti-BCMA antibody-drug conjugates and methods of use
US20240043928A1 (en) 2020-11-04 2024-02-08 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
EP4361136A4 (fr) * 2021-06-18 2025-08-13 Univ Cordoba Composé pour le traitement du glioblastome
CN113876771B (zh) * 2021-11-12 2022-09-23 中国医学科学院基础医学研究所 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用
WO2023131866A1 (fr) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarqueurs pour le syndrome myélodysplasique (mds) et leurs méthodes d'utilisation
EP4570796A1 (fr) 2022-11-07 2025-06-18 Eisai R&D Management Co., Ltd. Procédé de production d'un composé macrolide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
JP4459051B2 (ja) 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
CA2494536C (fr) 2002-07-31 2011-10-04 Mercian Corporation Substance active d'un macrolide cyclique a 12 chainons
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
BR0316746A (pt) 2002-11-29 2005-10-18 Mercian Corp Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550)
CN1886505A (zh) 2003-11-27 2006-12-27 美露香株式会社 参与大环内酯类化合物的羟化作用的dna
JP4695982B2 (ja) 2003-11-28 2011-06-08 財団法人神奈川科学技術アカデミー 肝癌の検出方法及び肝癌診断薬並びに癌治療薬
US20070199741A1 (en) 2004-07-02 2007-08-30 Kenji Noumi Combined Weighing Apparatus
US8008049B2 (en) 2004-07-20 2011-08-30 Eisai R&D Management Co., Ltd. DNA coding for polypeptide participating in biosynthesis of pladienolide
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
JPWO2007043621A1 (ja) 2005-10-13 2009-04-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 プラジエノライドｂ及びプラジエノライドｄの全合成方法
WO2008111464A1 (fr) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. Procédé pour l'examen d'une action d'un agent anti-cancéreux utilisant un défaut d'épissage en tant que mesure
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives

Also Published As

Publication number Publication date
RU2016148887A3 (fr) 2018-12-11
KR20160082256A (ko) 2016-07-08
EP3143016B1 (fr) 2018-12-12
CN107074827B (zh) 2020-12-18
JP2017505282A (ja) 2017-02-16
DK3143016T3 (en) 2019-04-08
RS58400B1 (sr) 2019-04-30
LT3143016T (lt) 2019-06-10
ZA201607354B (en) 2018-05-30
KR102146726B1 (ko) 2020-08-21
ES2712401T3 (es) 2019-05-13
TWI634115B (zh) 2018-09-01
JP6067943B1 (ja) 2017-01-25
TR201902328T4 (tr) 2019-03-21
AU2015259237A1 (en) 2016-11-10
BR112016026638A2 (fr) 2017-08-15
RU2019124012A (ru) 2019-08-12
KR102146726B9 (ko) 2026-02-05
AR100431A1 (es) 2016-10-05
RU2707730C2 (ru) 2019-11-29
AU2015259237B2 (en) 2019-08-15
CA2947754C (fr) 2024-01-02
HRP20190432T1 (hr) 2019-04-19
MX388580B (es) 2025-03-20
IL248529A0 (en) 2016-12-29
MX2020004476A (es) 2021-12-08
ME03417B (fr) 2020-01-20
MY195081A (en) 2023-01-09
MA39915B1 (fr) 2019-05-31
CY1121550T1 (el) 2020-05-29
RU2016148887A (ru) 2018-06-18
KR101710318B1 (ko) 2017-02-24
SI3143016T1 (sl) 2019-04-30
CL2016002835A1 (es) 2017-04-17
SMT201900158T1 (it) 2019-05-10
NZ725603A (en) 2023-11-24
US9481669B2 (en) 2016-11-01
HUE041838T2 (hu) 2019-05-28
IL248529B (en) 2019-11-28
EP3514154B1 (fr) 2022-08-03
MX2016014997A (es) 2017-06-29
MX373324B (es) 2020-05-04
NZ764190A (en) 2023-11-24
BR112016026638B1 (pt) 2022-08-02
JO3668B1 (ar) 2020-08-27
EP3514154A1 (fr) 2019-07-24
US20150329528A1 (en) 2015-11-19
SG11201609693XA (en) 2016-12-29
TW201625596A (zh) 2016-07-16
WO2015175594A1 (fr) 2015-11-19
CA2947754A1 (fr) 2015-11-19
PT3143016T (pt) 2019-02-27
PL3143016T3 (pl) 2019-04-30
KR101710318B9 (ko) 2026-02-06
EP3143016A1 (fr) 2017-03-22
UA119458C2 (uk) 2019-06-25
PE20170384A1 (es) 2017-05-11
PH12016502249A1 (en) 2017-02-06
CN107074827A (zh) 2017-08-18
KR20170021899A (ko) 2017-02-28
PH12016502249B1 (en) 2023-12-13

Similar Documents

Publication Publication Date Title
ME03417B (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA43827A (fr) Composés di-nucléotides cycliques et leurs procédés d'utilisation
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
EP3359168A4 (fr) Composés thérapeutiques et procédés
MA49861A (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
EP3665156A4 (fr) Composés, compositions et procédés
PL3558197T3 (pl) Wyroby chłonne zawierające laminaty zawierające elastomery wiązkowe
MA50063A (fr) Composés, compositions et procédés
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
EP2968440A4 (fr) Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
EP3337486A4 (fr) Composés deutérés et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
EP3387023A4 (fr) Procédés de récupération d'hydrocarbure
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
PL3247791T3 (pl) Uniwersalne komórki nkt
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
DK3341303T3 (da) Blisterpakning
EP3377060A4 (fr) Composés de pyrazole, procédés de production et utilisation
MA49560A (fr) Composés cétoniques bicycliques et leurs procédés d'utilisation
EP3303436A4 (fr) Hydrofluorooléfines et leurs procédés d'utilisation
DK3286260T3 (da) Polyolefinrør
EP3350196A4 (fr) Composés carborane et leurs procédés d'utilisation